Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of V-01 recombinant SARS-CoV-2 fusion protein vaccine in healthy adults
ChiCTR2100045107Phase 2Recruiting
- Sponsor
- Guangdong Provincial Center for Disease Control and Prevention
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of V-01 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Guangdong Provincial Center for Disease Control and Prevention. Primary endpoints: Positive conversion rate of serum anti-SARS-CoV-2 RBD binding antibody, Geometric mean titer of serum anti-SARS-CoV-2 RBD binding antibody and 4 more. Started Mar 2021; status: recruiting.
02
Drugs
V-01
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100045107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045107.